MET-PE Q1 2026 Earnings Call Summary

Adjusted Earnings: $1.6 billion, or $2.42 per share, an 18% increase year-over-year; adjusted EPS rose 23%.
Net Income: $1.1 billion, or $1.74 per share.
Adjusted Return on Equity: 17%, at the top end of the 15%-17% target range.
Direct Expense Ratio: 11.9%, improved from the previous year and below the 2026 target of 12.1%.
Variable Investment Income: $518 million, driven by strong private equity returns (2.9%).
Cash and Liquid Assets: $3.9 billion, at the high end of the liquidity target buffer ($3 billion to $4 billion).
Shareholder Returns: $1.1 billion returned through share repurchases and dividends.

New Frontier Strategy: Year 2 focuses on accelerating execution across businesses, with evidence of strong performance and disciplined capital management.
Group Benefits: Adjusted earnings of $439 million, up 19%, with strong sales growth (15%) and favorable life mortality trends.
Retirement & Income Solutions (RIS): Adjusted earnings of $451 million, up 11%, supported by strong variable investment income and new sales of $1.5 billion.
Asia Performance: Adjusted earnings of $487 million, a 31% increase, with Japan and Korea driving strong sales growth (22% and 44% respectively).
EMEA: Adjusted earnings of $110 million, up 33%, reflecting strong sales and operational efficiency.
MetLife Investment Management (MIM): Adjusted earnings of $47 million, up 68%, with a strong pipeline for future growth.

RIS Full-Year Guidance: Expected adjusted earnings between $1.6 billion to $1.8 billion.
Continued Growth: Anticipation of sustained momentum in Asia, though some moderation in growth rates expected due to strong prior year comparatives.
Expense Management: Confidence in maintaining the direct expense ratio below the annual target.

Investment Losses: Net investment losses impacted net income, primarily due to trading activity in the fixed maturity portfolio.
Market Volatility: Institutional client outflows of approximately $2 billion in MIM due to market conditions and integration challenges post-PineBridge acquisition.
Regulatory Scrutiny in Japan: Ongoing discussions with regulators regarding industry-wide issues, though no immediate impact on business results noted.
Disability Claims: Increased claims from new paid family leave programs and higher severity could necessitate future pricing adjustments.

Sustainability of Mortality Trends: Management indicated that favorable working-age mortality trends may be influenced by various factors, including COVID-19 effects and new treatments, but are cautiously optimistic about their sustainability.
Japan Regulatory Environment: Management reassured that while regulatory scrutiny is increasing, it does not currently affect business performance.
Disability Pricing: The ability to reprice 50% of the disability book annually provides flexibility, with no immediate need for broad repricing despite recent claims trends.
MIM Pipeline: Early integration of PineBridge shows promise, with positive feedback on cross-selling opportunities and a strong pipeline for new commitments.

This summary encapsulates MetLife's strong performance in Q1 2026 while highlighting strategic initiatives and potential challenges ahead.

MET-PE — MetLife, Inc.